H.U. Group Holdings,Inc. Q1 FY2026 earnings call

Overall Financial Results

• 1Q consolidated operating profit was 0.87 billion yen. Excluding 0.47 billion yen in M&A-related costs for the IVD segment acquisition, core operating profit was 1.34 billion yen, a large year-over-year increase. The quarter saw overall top-line growth and increased EBITDA/operating profit, though reported ordinary and net profit fell year-over-year due to non-operating factors.
• Reported net loss of 1.2 billion yen driven by a shift from prior-year foreign exchange gains to current-quarter foreign exchange losses, plus fixed asset write-off losses from the legacy mainframe shutdown, which was within management expectations against the full-year net profit plan of 5.5 billion yen.

Operational Milestones

• The H.U.Bioness Complex new facility and integrated IT system (for revenue recognition and billing management) is now fully operational. The shutdown of the 40+ year-old legacy mainframe system was completed at the end of June, eliminating legacy system maintenance costs starting in July.
• NEURO received the world's first FDA approval for its plasma-based pTau217 testing reagent for Alzheimer's disease. This test is faster and less invasive than existing amyloid PET or CSF testing, creating significant new customer value. Regulatory submissions are on track for Japan and Europe this year, with Indian approval already secured via a local partner and preparations underway for other global markets.

M&A Strategic Update

• The acquisition of US-based Plasma Services Group (based in New Jersey) completed in June 2025. The strategic purpose is to strengthen the CDMO business: the acquisition adds raw material capabilities H.U. Group did not previously hold, expands the range of CDMO service offerings, creates cross-selling opportunities from overlapping few customers between the two businesses, and enables in-house access to clinical samples for new reagent development to speed up innovation.

Efficiency and Profitability Improvement

• Pricing and service level optimization initiatives across segments are progressing steadily, with clear positive impact on margin expansion. Management will prioritize maximizing efficiency from the Akiruno Cube facility to accelerate profitability improvement going forward.

1. LTS Business: Grew revenue driven by strong demand for high-margin genetic testing and special testing. Achieved net profit growth after absorbing increased one-time costs and depreciation related to H.U.Bioness Complex, supported by margin expansion from service level and pricing optimization. Excluding 0.9 billion yen in one-time hypercare costs, the segment reached operating profit break-even on an underlying basis. COVID-19 related revenue has fallen to ~0.1 billion yen per quarter, a negligible portion of overall sales.
2. IVD Business: Reported a slight top-line decline due to yen appreciation and lower COVID-19 related revenue, but the underlying core business grew. NEURO-related revenue reached 1.7 billion yen, doubling year-over-year, with Plasma-based reagent revenue tripling year-over-year. The CDMO sub-segment grew 4% in local currency terms (excluding negative foreign exchange impact on yen-denominated reporting). Profit was roughly flat year-over-year after accounting for 0.47 billion yen in M&A-related costs for the Plasma Services Group acquisition, in line with plan.
3. HS Business: Achieved both revenue and profit growth. Growth was led by steady performance in sterilization and surgery-related businesses, plus contribution from Gaea Medicare, which was consolidated as a subsidiary in December 2024. Pricing optimization also supported margin expansion in the segment.

• Overall 1Q results are in line with management's plan, which had explicitly anticipated a softer 1Q due to pre-budgeted one-time Akiruno Cube costs. M&A-related costs will be offset by stronger-than-expected profit generation from core businesses (led by NEURO) to get back on plan by the fourth quarter. All contract renegotiations for pricing adjustments will be completed within the current fiscal year, with the full impact of changes budgeted into the full-year plan, though the exact monthly timing of revenue recognition will vary by customer contract. Management targets reaching break-even for the LTS segment in the second quarter after the elimination of 0.9 billion yen in 1Q one-time costs.

• Pricing renegotiation with hospital customers (the segment's core client base) is complex, as contract renewal dates vary per hospital and require per-test negotiation, leading to delayed full realization of pricing adjustment benefits compared to simpler retail/primary care segments. Remaining software bugs in the new H.U.Bioness Complex IT system require ongoing remediation work, keeping near-term running costs elevated even after the legacy system shutdown. Foreign exchange swings can create significant volatility in non-operating income/expense and consolidated overseas segment revenue, as seen in the current quarter's ordinary profit decline driven by yen appreciation.

Q: The LTS segment had 0.9 billion yen in 1Q one-time costs leading to a reported operating loss that implies underlying profitability. What is the timeline for price adjustment effects, and can the segment generate material profit starting from 2Q? Is the current reliance on special testing growth sustainable?

A: Some price adjustment benefits already took effect in 1Q, with roughly 70% of customer contract renewals completed to date. Full effects will largely be realized in the second half of the fiscal year, so it is too early to quantify full impact, which will be disclosed with 2Q results. The 0.9 billion yen in one-time 1Q costs will not repeat, but remaining IT system bugs mean elevated running costs will persist. Management targets reaching roughly break-even for the segment in 2Q.

Q: Is it correct that most of the price adjustment benefits will not appear until the second half of this fiscal year or next year, and how is this incorporated into the full-year plan?

A: All contract renewals will be completed within the current fiscal year, no changes are planned to carry over to next year. The full-year plan already incorporates a reasonable estimate of price adjustment effects based on current renewal progress, though the exact realized amount will vary based on the timing of individual customer contract renewals.